FDAnews
www.fdanews.com/articles/81352-xtlbio-starts-hepatitis-c-drug-trial

XTLBIO STARTS HEPATITIS C DRUG TRIAL

October 3, 2005

XTL Biopharmaceuticals has initiated a Phase Ia clinical trial of XTL-6865 for the treatment of hepatitis C (HCV). This trial is being conducted under an investigational new drug application, filed with the FDA in April. The trial is a multicenter trial and will be conducted in the U.S. and Israel.

XTL-6865 is being developed to prevent HCV re-infection following liver transplants and for the treatment of chronic HCV disease. XTL-6865 is a combination of two fully human monoclonal antibodies against the hepatitis C virus E2 envelope protein. A single-antibody version of this product was tested in a pilot clinical program that included both Phase I and Phase II clinical trials and provided preliminary evidence of antiviral activity in humans.